Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Waksal Buys Back Into Pharmaceuticals

by Rick Mullin
November 1, 2010 | A version of this story appeared in Volume 88, Issue 44

Kadmon Pharmaceuticals, headed by Sam Waksal, the former ImClone Systems CEO who was imprisoned for an insider trading scheme that also snared Martha Stewart, has acquired Three Rivers Pharmaceuticals, a privately held drug company based in Warrendale, Pa., for an undisclosed sum. Three Rivers manufactures treatments for hepatitis C and a fungal infection. “Hepatitis treatment is on the verge of major change,” Waksal says. “With Three Rivers as a cornerstone, Kadmon will play an important role in the evolution of this global market.” The Securities & Exchange Commission has barred Waksal from serving as the director or officer of any public company. Kadmon’s lead investor is SBI Holdings of Japan.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.